Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 14;11(6):e5087.
doi: 10.1097/GOX.0000000000005087. eCollection 2023 Jun.

No Cancer Occurrences in 10-year Follow-up after Prophylactic Nipple-sparing Mastectomy

Carter J Boyd  1 , Jonathan M Bekisz  1 , Sruthi Ramesh  1 , Kshipra Hemal  1 , Amber A Guth  2 , Deborah M Axelrod  2 , Richard L Shapiro  2 , Karen Hiotis  2 , Freya R Schnabel  2 , Mihye Choi  1 , Nolan S Karp  1
Affiliations

No Cancer Occurrences in 10-year Follow-up after Prophylactic Nipple-sparing Mastectomy

Carter J Boyd et al. Plast Reconstr Surg Glob Open. .

Abstract

Prophylactic nipple-sparing mastectomies (NSM) have become increasingly common, although there is little long-term data on its efficacy in prevention of breast cancer. The objective of this study was to assess the incidence of breast cancer in a cohort of patients undergoing prophylactic NSM with a median follow-up of 10 years.

Methods: Patients receiving prophylactic NSM at a single institution from 2006 to 2019 were included in a retrospective nature. Patient demographics, genetic mutations, operative details, and specimen pathology were recorded, and all postoperative patient visits and documentation were screened for cancer occurrence. Descriptive statics were performed where appropriate.

Results: Two hundred eighty-four prophylactic NSMs were performed on 228 patients with a median follow-up of 120.5 ± 15.7 months. Roughly, a third of patients had a known genetic mutation, with 21% BRCA1 and 12% BRCA2. The majority (73%) of prophylactic specimens had no abnormal pathology. The most commonly observed pathologies were atypical lobular hyperplasia (10%) and ductal carcinoma in situ (7%). Cancer was identified in 10% of specimens, with only one case of lymphovascular invasion. Thus far, there have been no incidences of locoregional breast cancer occurrence in this cohort.

Conclusions: The long-term breast cancer occurrence rate in this cohort of prophylactic NSM patients at the time of this study is negligible. Despite this, continued surveillance of these patients is necessary until lifetime risk of occurrence following NSM has been established.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial interest to declare in relation to the content of this article.

References

    1. Salibian AA, Frey JD, Choi M, et al. . BRCA mutations in the young, high-risk female population: genetic testing, management of prophylactic therapies, and implications for plastic surgeons. Plast Reconstr Surg. 2018;141:1341–1350. - PubMed
    1. Cobain EF, Milliron KJ, Merajver SD. Updates on breast cancer genetics: clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer. Semin Oncol. 2016;43:528–535. - PubMed
    1. Baretta Z, Mocellin S, Goldin E, et al. . Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltim). 2016;95:e4975. - PMC - PubMed
    1. Frey JD, Salibian AA, Lee J, et al. . Oncologic trends, outcomes, and risk factors for locoregional recurrence: an analysis of tumor-to-nipple distance and critical factors in therapeutic nipple-sparing mastectomy. Plast Reconstr Surg. 2019;143:1575–1585. - PubMed
    1. Lanitis S, Tekkis PP, Sgourakis G, et al. . Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg. 2010;251:632–639. - PubMed